For example, in NSCLC, KRAS mutations account for 20.4% of KRAS, and the dominant substitution is G12C (glycine (GGT) to cysteine (TGT)), while KRAS mutation accounts for up to 67.6% of KRAS in pancreatic adenocarcinoma, and KRAS (G12D) is the dominant mutant subtype. Here, KRAS is linked to non-small cell lung carcinoma.